REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Clinical trials for REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a two-step treatment for adults with large B-cell lymphoma that returned or didn't respond to prior therapy. First, patients receive tafasitamab (an antibody that targets cancer cells) plus lenalidomide (a drug that helps the immune system fight cancer). Then, th…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 17, 2026 06:52 UTC
-
New drug cocktail aims to beat back tough blood cancers
Disease control Recruiting nowThis study tests a mix of six chemotherapy drugs in people whose acute lymphoblastic leukemia, lymphoblastic lymphoma, or related blood cancers have returned or stopped responding to treatment. The goal is to see if this combination can shrink or control the cancer and to check f…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 06:51 UTC
-
New Five-Drug cocktail shows promise for Hard-to-Treat lymphomas
Disease control Recruiting nowThis study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive lymphomas that have come back or not responded to prior therapy. The goal is to see how many patients achieve complete …
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Could a poop pill make cancer therapy work better?
Disease control Recruiting nowThis study tests whether a fecal transplant from healthy donors can repair gut damage caused by antibiotics and chemotherapy in lymphoma patients receiving CAR T-cell therapy. About 56 adults with relapsed or hard-to-treat lymphoma will be randomly assigned to get either the tran…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New drug targets Hard-to-Treat lymphoma in early trial
Disease control Recruiting nowThis early-phase trial is testing a drug called tegavivint in about 18 people whose large B-cell lymphoma has come back or stopped responding to standard treatments. The drug works by blocking certain enzymes that cancer cells need to grow. The main goals are to find the safest d…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE1 • Sponsor: Lapo Alinari • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New drug combo aims to outsmart tough lymphoma
Disease control Recruiting nowThis study is for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments. It tests a combination of two drugs: epcoritamab, which helps the immune system attack cancer cells, and ibrutinib, which blocks signals that help cance…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated May 11, 2026 20:47 UTC